APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma

Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts

(2015) Matthew Read et al.   ANNALS OF SURGICAL ONCOLOGY

An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo

(2015) Brandon J. Aubrey et al.   Cell Reports

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

Long-term recurrence of neoplasia and Barrett's epithelium after complete endoscopic resection

(2014) Mario Anders et al.   GUT

Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis

(2014) Jamie M J Weaver et al.   NATURE GENETICS

Variability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma

(2013) D N T Aryee et al.   BRITISH JOURNAL OF CANCER

Characterization of a Novel Tumorigenic Esophageal Adenocarcinoma Cell Line: OANC1

(2013) Nicholas J. Clemons et al.   DIGESTIVE DISEASES AND SCIENCES

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors

(2013) Karen E. Sheppard et al.   EUROPEAN JOURNAL OF CANCER

Barrett Esophagus and Risk of Esophageal Cancer

(2013) Stuart Jon Spechler   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa

(2013) Manujendra N. Saha et al.   MOLECULAR CANCER THERAPEUTICS

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity

(2013) Austin M Dulak et al.   NATURE GENETICS

Genome engineering using the CRISPR-Cas9 system

(2013) F Ann Ran et al.   Nature Protocols

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy

(2013) K. Shchors et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

(2013) X Peng et al.   Cell Death & Disease

The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends

(2012) A. P. Thrift et al.   ANNALS OF ONCOLOGY

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

(2011) Katrin M Sjoquist et al.   LANCET ONCOLOGY

Caspase-3 triggers a TPCK-sensitive protease pathway leading to degradation of the BH3-only protein puma

(2010) Abbas Hadji et al.   APOPTOSIS

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study

(2010) Koroush Madani et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73

(2010) N Rökaeus et al.   ONCOGENE

p53 Genotype Predicts Response to Chemotherapy in Patients with Squamous Cell Carcinoma of the Esophagus

(2009) Makoto Yamasaki et al.   ANNALS OF SURGICAL ONCOLOGY

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Structural and Functional Basis for Therapeutic Modulation of p53 Signaling

(2008) E. A. Bassett et al.   CLINICAL CANCER RESEARCH